Safe and effective use of plerixafor plus G-CSF in dialysis-dependent renal failure.
Pinto
Valeria
V
Castelli
Andrea
A
Gaidano
Gianluca
G
Conconi
Annarita
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001596:Benzylamines; D003131:Combined Modality Therapy; D000080027:Cyclams; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000628:therapy*; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D019653:Myeloablative Agonists / Q000627:therapeutic use; D036102:Peripheral Blood Stem Cell Transplantation; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors; D006435:Renal Dialysis; D013792:Thalidomide / Q000008:administration & dosage; D019172:Transplantation Conditioning
D001596:Benzylamines; C527276:CXCR4 protein, human; D000080027:Cyclams; D006571:Heterocyclic Compounds; D019653:Myeloablative Agonists; D019718:Receptors, CXCR4; D016179:Granulocyte Colony-Stimulating Factor; D013792:Thalidomide; D003907:Dexamethasone; D008558:Melphalan; C088327:plerixafor